1
|
Ali A, Bauser M, Bertrand S, Blackaby W, Boss C, Bossart M, Hall A, Binch H, Czechtizky W, Gijsen H, Haning H, Hartung IV, Kilburn P, Lassalle G, Lücking U, Mack J, Missbach M, Otsomaa L, Torrens A, Wagner M, Walter M, Weinstabl H, van Hijfte L, von Nussbaum F. European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in Europe. ChemMedChem 2023; 18:e202300127. [PMID: 37276375 DOI: 10.1002/cmdc.202300127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Revised: 05/16/2023] [Indexed: 07/18/2023]
Abstract
The status of industrial Medicinal Chemistry was discussed with European Medicinal Chemistry Leaders from large to mid-sized pharma and CRO companies as well as biotechs. The chemical modality space has expanded recently from small molecules to address new challenging targets. Besides the classical SAR/SPR optimization of drug molecules also their 'greenness' has increasing importance. The entire pharma discovery ecosystem has developed significantly. Beyond pharma and academia new key players such as Biotech and integrated CROs as well as Digital companies have appeared and are now to a large extend fueled by VC money. Digitalization is happening everywhere but surprisingly did not change speed and success rates of projects so far. Future Medicinal Chemists will still have to be excellent synthetic chemists but in addition they must be knowledgeable in new computational areas such as data sciences. Their ability to collaborate and to work in teams is key.
Collapse
Affiliation(s)
- Amjad Ali
- External Discovery Chemistry, Merck and Co. Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | - Marcus Bauser
- Research & Early Development, Global R&D, Leo Pharma, Industriparken 55, 2750, Ballerup, Denmark
| | - Sophie Bertrand
- Medicinal Chemistry, Medicine Design, R&D, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Wesley Blackaby
- Chemistry and Analytical Sciences, Drug Design and Small Molecule Unit, Servier Research Institute, 125 Chemin de Ronde, 78290, Croissy sur Seine, France
| | - Christoph Boss
- Drug Discovery Chemistry, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil/BK, Switzerland
| | - Martin Bossart
- Synthetic Medicinal Modalities, Sanofi, Industriepark Höchst G838, 65926, Frankfurt, Germany
| | - Adrian Hall
- Medicinal Chemistry, UCB Pharma, Chemin Du Foriest 1, 1420, Braine-l'Alleud, Belgium
| | - Hayley Binch
- Medicinal Chemistry, Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland
| | - Werngard Czechtizky
- Medicinal Chemistry, Respiratory and Immunology, AstraZeneca, Pepparedsleden 1, 43183, Göteborg, Sweden
| | - Harrie Gijsen
- Discovery Chemistry, Therapeutics Discovery, Janssen Research & Development, A division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium
| | - Helmut Haning
- Research & Development, Drug Discovery Sciences, Medicinal Chemistry, Bayer AG, Pharmaceuticals, < postCode/>42096, Wuppertal, Germany
| | - Ingo V Hartung
- Medicinal Chemistry & Drug Design, Merck Healthcare KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany
| | - Paul Kilburn
- Medicinal Chemistry and Translational DMPK, Lundbeck, Ottiliavej 9, 2500, Valby, Denmark
| | - Gilbert Lassalle
- Medicinal Chemistry, Evotec (France), SAS, Campus Curie, 195 Route d'Espagne, 31036, Toulouse Cedex, France
| | - Ulrich Lücking
- Chemistry, FoRx Therapeutics, Lichtstrasse 35, 4056, Basel, Switzerland
| | - Jürgen Mack
- Medicinal Chemistry, Boehringer Ingelheim, Birkendorfer Str. 65, 88400, Biberach, Germany
| | - Martin Missbach
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research (NIBR), 4002, Basel, Switzerland
| | - Leena Otsomaa
- Medicine Design, R&D, Orion Corporation, Orion Pharma, Orionintie 1, 02200, Espoo, Finland
| | - Antoni Torrens
- Chemical Collaborations & Strategic Alliances, ABAC Therapeutics S.L., Joan XXIII, 10, 08950, Esplugues de Llobregat. Barcelona, Spain
| | - Michael Wagner
- Chemistry and Drug Discovery, Dewpoint Therapeutics GmbH, Industriepark Hoechst, G830, 65926, Frankfurt, Germany
| | - Magnus Walter
- Chemical Sciences and Process Development, Monte Rosa Therapeutics AG, Klybeckstrasse 191, WKL-136.3, 4057, Basel, Switzerland
| | - Harald Weinstabl
- Medicinal Chemistry, Boehringer Ingelheim, Dr. Boehringer Gasse 5-11, 1121, Vienna, Austria
| | - Luc van Hijfte
- Drug Discovery, Symeres, Kerkenbos 1013, 6546, BB Nijmegen, The Netherlands
| | - Franz von Nussbaum
- Life Science Chemistry, Nuvisan ICB GmbH, Müllerstr. 178, 13353, Berlin, Germany
| |
Collapse
|
2
|
Lücking U. Frontispiece: New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective. Chemistry 2022. [DOI: 10.1002/chem.202285661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Ulrich Lücking
- FoRx Therapeutics AG Lichtstrasse 35, WSJ-350.3.05 4056 Basel Switzerland
| |
Collapse
|
3
|
Lücking U. New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective**. Chemistry 2022; 28:e202201993. [DOI: 10.1002/chem.202201993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Ulrich Lücking
- FoRx Therapeutics AG Lichtstrasse 35, WSJ-350.3.05 4056 Basel Switzerland
| |
Collapse
|
4
|
Berger M, Wortmann L, Buchgraber P, Lücking U, Zitzmann-Kolbe S, Wengner AM, Bader B, Bömer U, Briem H, Eis K, Rehwinkel H, Bartels F, Moosmayer D, Eberspächer U, Lienau P, Hammer S, Schatz CA, Wang Q, Wang Q, Mumberg D, Nising CF, Siemeister G. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. J Med Chem 2021; 64:12723-12737. [PMID: 34428039 DOI: 10.1021/acs.jmedchem.1c00762] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Eukaryotes have evolved two major pathways to repair potentially lethal DNA double-strand breaks. Homologous recombination represents a precise, DNA-template-based mechanism available during the S and G2 cell cycle phase, whereas non-homologous end joining, which requires DNA-dependent protein kinase (DNA-PK), allows for fast, cell cycle-independent but less accurate DNA repair. Here, we report the discovery of BAY-8400, a novel selective inhibitor of DNA-PK. Starting from a triazoloquinoxaline, which had been identified as a hit from a screen for ataxia telangiectasia and Rad3-related protein (ATR) inhibitors with inhibitory activity against ATR, ATM, and DNA-PK, lead optimization efforts focusing on potency and selectivity led to the discovery of BAY-8400. In in vitro studies, BAY-8400 showed synergistic activity of DNA-PK inhibition with DNA damage-inducing targeted alpha therapy. Combination of PSMA-targeted thorium-227 conjugate BAY 2315497 treatment of human prostate tumor-bearing mice with BAY-8400 oral treatment increased antitumor efficacy, as compared to PSMA-targeted thorium-227 conjugate monotherapy.
Collapse
Affiliation(s)
- Markus Berger
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Lars Wortmann
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Philipp Buchgraber
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Ulrich Lücking
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | | | - Antje M Wengner
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Benjamin Bader
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Ulf Bömer
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Hans Briem
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Knut Eis
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Hartmut Rehwinkel
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Florian Bartels
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Dieter Moosmayer
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Uwe Eberspächer
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Philip Lienau
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Stefanie Hammer
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Christoph A Schatz
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Qiuwen Wang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Qi Wang
- WuXi AppTec (Wuhan) Co., Ltd., 666 Gaoxin Road, East Lake High-tech Development Zone, Wuhan 430075, P. R. China
| | - Dominik Mumberg
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Carl F Nising
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Gerhard Siemeister
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| |
Collapse
|
5
|
Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U, Schäfer M, Ince S, Mumberg D, Scholz A, Izumi R, Hwang S, von Nussbaum F. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. J Med Chem 2021; 64:11651-11674. [PMID: 34264057 DOI: 10.1021/acs.jmedchem.1c01000] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Selective inhibition of exclusively transcription-regulating positive transcription elongation factor b/CDK9 is a promising new approach in cancer therapy. Starting from atuveciclib, the first selective CDK9 inhibitor to enter clinical development, lead optimization efforts aimed at identifying intravenously (iv) applicable CDK9 inhibitors with an improved therapeutic index led to the discovery of the highly potent and selective clinical candidate VIP152. The evaluation of various scaffold hops was instrumental in the identification of VIP152, which is characterized by the underexplored benzyl sulfoximine group. VIP152 exhibited the best preclinical overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats upon once weekly iv administration. VIP152 has entered clinical trials for the treatment of cancer with promising longterm, durable monotherapy activity in double-hit diffuse large B-cell lymphoma patients.
Collapse
Affiliation(s)
- Ulrich Lücking
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Dirk Kosemund
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Niels Böhnke
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Philip Lienau
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Gerhard Siemeister
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Karsten Denner
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Rolf Bohlmann
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Hans Briem
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Ildiko Terebesi
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Ulf Bömer
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Martina Schäfer
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Stuart Ince
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Dominik Mumberg
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Arne Scholz
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| | - Raquel Izumi
- Vincerx Pharma, Inc., 260 Sheridan Avenue, Suite 400, Palo Alto, California 94306, United States
| | - Stuart Hwang
- Vincerx Pharma, Inc., 260 Sheridan Avenue, Suite 400, Palo Alto, California 94306, United States
| | - Franz von Nussbaum
- Pharmaceuticals, Research and Development, Bayer Pharma AG, Müllerstr. 178, Berlin 13353, Germany
| |
Collapse
|
6
|
Greed S, Briggs EL, Idiris FIM, White AJP, Lücking U, Bull JA. Synthesis of Highly Enantioenriched Sulfonimidoyl Fluorides and Sulfonimidamides by Stereospecific Sulfur-Fluorine Exchange (SuFEx) Reaction. Chemistry 2020; 26:12533-12538. [PMID: 32428384 PMCID: PMC7590120 DOI: 10.1002/chem.202002265] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Indexed: 01/12/2023]
Abstract
Sulfonimidamides present exciting opportunities as chiral isosteres of sulfonamides, with potential for additional directional interactions. Here, we present the first modular enantioselective synthesis of sulfonimidamides, including the first stereoselective synthesis of enantioenriched sulfonimidoyl fluorides, and studies on their reactivity. A new route to sulfonimidoyl fluorides is presented from solid bench-stable, N-Boc-sulfinamide (Boc=tert-butyloxycarbonyl) salt building blocks. Enantioenriched arylsulfonimidoyl fluorides are shown to be readily racemised by fluoride ions. Conditions are developed, which trap fluoride and enable the stereospecific reaction of sulfonimidoyl fluorides with primary and secondary amines (100 % es, es=enantiospecificity) generating sulfonimidamides with up to 99 % ee. Aryl and alkyl sulfonimidoyl fluoride reagents are suitable for mild late stage functionalisation reactions, exemplified by coupling with a selection of complex amines in marketed drugs.
Collapse
Affiliation(s)
- Stephanie Greed
- Department of ChemistryImperial College LondonMolecular Sciences Research HubWhite City CampusWood LaneLondonW12 0BZUK
| | - Edward L. Briggs
- Department of ChemistryImperial College LondonMolecular Sciences Research HubWhite City CampusWood LaneLondonW12 0BZUK
| | - Fahima I. M. Idiris
- Department of ChemistryImperial College LondonMolecular Sciences Research HubWhite City CampusWood LaneLondonW12 0BZUK
| | - Andrew J. P. White
- Department of ChemistryImperial College LondonMolecular Sciences Research HubWhite City CampusWood LaneLondonW12 0BZUK
| | - Ulrich Lücking
- Bayer AGPharmaceuticals DivisionDrug DiscoveryMüllerstr. 17813353BerlinGermany
| | - James A. Bull
- Department of ChemistryImperial College LondonMolecular Sciences Research HubWhite City CampusWood LaneLondonW12 0BZUK
| |
Collapse
|
7
|
Lücking U, Wortmann L, Wengner AM, Lefranc J, Lienau P, Briem H, Siemeister G, Bömer U, Denner K, Schäfer M, Koppitz M, Eis K, Bartels F, Bader B, Bone W, Moosmayer D, Holton SJ, Eberspächer U, Grudzinska-Goebel J, Schatz C, Deeg G, Mumberg D, von Nussbaum F. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem 2020; 63:7293-7325. [PMID: 32502336 DOI: 10.1021/acs.jmedchem.0c00369] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The ATR kinase plays a key role in the DNA damage response by activating essential signaling pathways of DNA damage repair, especially in response to replication stress. Because DNA damage and replication stress are major sources of genomic instability, selective ATR inhibition has been recognized as a promising new approach in cancer therapy. We now report the identification and preclinical evaluation of the novel, clinical ATR inhibitor BAY 1895344. Starting from quinoline 2 with weak ATR inhibitory activity, lead optimization efforts focusing on potency, selectivity, and oral bioavailability led to the discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344, which exhibited strong monotherapy efficacy in cancer xenograft models that carry certain DNA damage repair deficiencies. Moreover, combination treatment of BAY 1895344 with certain DNA damage inducing chemotherapy resulted in synergistic antitumor activity. BAY 1895344 is currently under clinical investigation in patients with advanced solid tumors and lymphomas (NCT03188965).
Collapse
Affiliation(s)
- Ulrich Lücking
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Lars Wortmann
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Antje M Wengner
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Julien Lefranc
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Philip Lienau
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Hans Briem
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Gerhard Siemeister
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Ulf Bömer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Karsten Denner
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Martina Schäfer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Marcus Koppitz
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Knut Eis
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Florian Bartels
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Benjamin Bader
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Wilhelm Bone
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Dieter Moosmayer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Simon J Holton
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Uwe Eberspächer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | | | - Christoph Schatz
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Gesa Deeg
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Dominik Mumberg
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Franz von Nussbaum
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| |
Collapse
|
8
|
Boulard E, Zibulski V, Oertel L, Lienau P, Schäfer M, Ganzer U, Lücking U. Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties. Chemistry 2020; 26:4378-4388. [PMID: 31961028 DOI: 10.1002/chem.201905461] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 01/17/2020] [Indexed: 12/13/2022]
Abstract
A short synthetic approach with broad scope to access five- to seven-membered cyclic sulfoximines in only two to three steps from readily available thiophenols is reported. Thus, simple building blocks were converted to complex molecular structures by a sequence of S-alkylation and one-pot sulfoximine formation, followed by intramolecular cyclization. Seventeen structurally diverse cyclic sulfoximines were prepared in high overall yields. In vitro evaluation of these underrepresented, three-dimensional, cyclic sulfoximines with respect to properties relevant to medicinal chemistry did not reveal any intrinsic flaw for application in drug discovery.
Collapse
Affiliation(s)
- Emilie Boulard
- Bâtiment Hubert Curien 43, CPE Lyon-Campus LyonTech/la Doua, boulevard du 11 Novembre 1918, 69616, Villeurbanne Cedex, France
| | - Vivien Zibulski
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| | - Luisa Oertel
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| | - Philip Lienau
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| | - Martina Schäfer
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| | - Ursula Ganzer
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| | - Ulrich Lücking
- Pharmaceuticals Division, Drug Discovery Department, Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany
| |
Collapse
|
9
|
Wortmann L, Lindenthal B, Muhn P, Walter A, Nubbemeyer R, Heldmann D, Sobek L, Morandi F, Schrey AK, Moosmayer D, Günther J, Kuhnke J, Koppitz M, Lücking U, Röhn U, Schäfer M, Nowak-Reppel K, Kühne R, Weinmann H, Langer G. Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo. J Med Chem 2019; 62:10321-10341. [PMID: 31670515 DOI: 10.1021/acs.jmedchem.9b01382] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The human luteinizing hormone receptor (hLH-R) is a member of the glycoprotein hormone family of G-protein-coupled receptors (GPCRs), activated by luteinizing hormone (hLH) and essentially involved in the regulation of sex hormone production. Thus, hLH-R represents a valid target for the treatment of sex hormone-dependent cancers and diseases (polycystic ovary syndrome, uterine fibroids, endometriosis) as well as contraception. Screening of the Bayer compound library led to the discovery of tetrahydrothienopyridine derivatives as novel, small-molecule (SMOL) hLH-R inhibitors and to the development of BAY-298, the first nanomolar hLH-R antagonist reducing sex hormone levels in vivo. Further optimization of physicochemical, pharmacokinetic, and safety parameters led to the identification of BAY-899 with an improved in vitro profile and proven efficacy in vivo. BAY-298 and BAY-899 serve as valuable tool compounds to study hLH-R signaling in vitro and to interfere with the production of sex hormones in vivo.
Collapse
Affiliation(s)
- Lars Wortmann
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | | | - Peter Muhn
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | - Alexander Walter
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | | | - Dieter Heldmann
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | - Lothar Sobek
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | - Federica Morandi
- Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) , Robert-Rössle Strasse 10 , Campus Berlin-Buch, 13125 Berlin , Germany
| | - Anna K Schrey
- Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) , Robert-Rössle Strasse 10 , Campus Berlin-Buch, 13125 Berlin , Germany
| | - Dieter Moosmayer
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | - Judith Günther
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | - Joachim Kuhnke
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | - Marcus Koppitz
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | - Ulrich Lücking
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | - Ulrike Röhn
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | - Martina Schäfer
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | | | - Ronald Kühne
- Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) , Robert-Rössle Strasse 10 , Campus Berlin-Buch, 13125 Berlin , Germany
| | - Hilmar Weinmann
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| | - Gernot Langer
- Bayer AG, Research & Development, Pharmaceuticals , 13353 Berlin , Germany
| |
Collapse
|
10
|
Wengner AM, Siemeister G, Lücking U, Lefranc J, Wortmann L, Lienau P, Bader B, Bömer U, Moosmayer D, Eberspächer U, Golfier S, Schatz CA, Baumgart SJ, Haendler B, Lejeune P, Schlicker A, von Nussbaum F, Brands M, Ziegelbauer K, Mumberg D. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models. Mol Cancer Ther 2019; 19:26-38. [PMID: 31582533 DOI: 10.1158/1535-7163.mct-19-0019] [Citation(s) in RCA: 111] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Revised: 07/05/2019] [Accepted: 09/27/2019] [Indexed: 11/16/2022]
Abstract
The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells. DDR deficiencies can promote tumorigenesis but concurrently may increase dependence on alternative repair pathways. The ataxia telangiectasia and Rad3-related (ATR) kinase plays a central role in the DDR by activating essential signaling pathways of DNA damage repair. Here, we studied the effect of the novel selective ATR kinase inhibitor BAY 1895344 on tumor cell growth and viability. Potent antiproliferative activity was demonstrated in a broad spectrum of human tumor cell lines. BAY 1895344 exhibited strong monotherapy efficacy in cancer xenograft models that carry DNA damage repair deficiencies. The combination of BAY 1895344 with DNA damage-inducing chemotherapy or external beam radiotherapy (EBRT) showed synergistic antitumor activity. Combination treatment with BAY 1895344 and DDR inhibitors achieved strong synergistic antiproliferative activity in vitro, and combined inhibition of ATR and PARP signaling using olaparib demonstrated synergistic antitumor activity in vivo Furthermore, the combination of BAY 1895344 with the novel, nonsteroidal androgen receptor antagonist darolutamide resulted in significantly improved antitumor efficacy compared with respective single-agent treatments in hormone-dependent prostate cancer, and addition of EBRT resulted in even further enhanced antitumor efficacy. Thus, the ATR inhibitor BAY 1895344 may provide new therapeutic options for the treatment of cancers with certain DDR deficiencies in monotherapy and in combination with DNA damage-inducing or DNA repair-compromising cancer therapies by improving their efficacy.
Collapse
Affiliation(s)
- Antje M Wengner
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
| | | | - Ulrich Lücking
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Julien Lefranc
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Lars Wortmann
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Philip Lienau
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Benjamin Bader
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Ulf Bömer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Dieter Moosmayer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Uwe Eberspächer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Sven Golfier
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | | | - Simon J Baumgart
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Bernard Haendler
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Pascale Lejeune
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Andreas Schlicker
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | | | - Michael Brands
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Karl Ziegelbauer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Dominik Mumberg
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| |
Collapse
|
11
|
Lücking U. Neglected sulfur(vi) pharmacophores in drug discovery: exploration of novel chemical space by the interplay of drug design and method development. Org Chem Front 2019. [DOI: 10.1039/c8qo01233d] [Citation(s) in RCA: 131] [Impact Index Per Article: 26.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The key learnings of the utilization of sulfoximines, sulfondiimines and sulfonimidamides in drug discovery at Bayer AG are shared.
Collapse
Affiliation(s)
- U. Lücking
- Bayer AG
- Pharmaceuticals Division
- Drug Discovery
- 13353 Berlin
- Germany
| |
Collapse
|
12
|
Izzo F, Schäfer M, Lienau P, Ganzer U, Stockman R, Lücking U. Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation of N-Functionalized Tertiary Sulfonimidamides. Chemistry 2018; 24:9295-9304. [PMID: 29726583 PMCID: PMC6055826 DOI: 10.1002/chem.201801557] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Revised: 05/03/2018] [Indexed: 01/02/2023]
Abstract
An unprecedented set of structurally diverse sulfonimidamides (47 compounds) has been prepared by various N-functionalization reactions of tertiary =NH sulfonimidamide 2 aa. These N-functionalization reactions of model compound 2 aa include arylation, alkylation, trifluoromethylation, cyanation, sulfonylation, alkoxycarbonylation (carbamate formation) and aminocarbonylation (urea formation). Small molecule X-ray analyses of selected N-functionalized products are reported. To gain further insight into the properties of sulfonimidamides relevant to medicinal chemistry, a variety of structurally diverse reaction products were tested in selected in vitro assays. The described N-functionalization reactions provide a short and efficient approach to structurally diverse sulfonimidamides which have been the subject of recent, growing interest in the life sciences.
Collapse
Affiliation(s)
- Flavia Izzo
- School of Chemistry, University of Nottingham, University Park, Nottingham, NG7 2RD, UK
| | - Martina Schäfer
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Philip Lienau
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Ursula Ganzer
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Robert Stockman
- School of Chemistry, University of Nottingham, University Park, Nottingham, NG7 2RD, UK
| | - Ulrich Lücking
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| |
Collapse
|
13
|
Izzo F, Schäfer M, Lienau P, Ganzer U, Stockman R, Lücking U. Cover Feature: Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation of N-Functionalized Tertiary Sulfonimidamides (Chem. Eur. J. 37/2018). Chemistry 2018. [DOI: 10.1002/chem.201802737] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Flavia Izzo
- School of Chemistry; University of Nottingham; University Park Nottingham NG7 2RD UK
| | - Martina Schäfer
- Bayer AG; Pharmaceuticals Division; Drug Discovery; Müllerstr. 178 13353 Berlin Germany
| | - Philip Lienau
- Bayer AG; Pharmaceuticals Division; Drug Discovery; Müllerstr. 178 13353 Berlin Germany
| | - Ursula Ganzer
- Bayer AG; Pharmaceuticals Division; Drug Discovery; Müllerstr. 178 13353 Berlin Germany
| | - Robert Stockman
- School of Chemistry; University of Nottingham; University Park Nottingham NG7 2RD UK
| | - Ulrich Lücking
- Bayer AG; Pharmaceuticals Division; Drug Discovery; Müllerstr. 178 13353 Berlin Germany
| |
Collapse
|
14
|
Göthert JR, Imsak R, Möllmann M, Kesper S, Göbel M, Dührsen U, Scholz A, Lücking U, Baumann M, Unger A, Schultz-Fademrecht C, Klebl B, Eickhoff J, Choidas A, Dürig J. Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia. Oncotarget 2018; 9:26353-26369. [PMID: 29899864 PMCID: PMC5995184 DOI: 10.18632/oncotarget.25293] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2017] [Accepted: 04/07/2018] [Indexed: 12/23/2022] Open
Abstract
Onset of progression even during therapy with novel drugs remains an issue in chronic lymphocytic leukemia (CLL). Thus, there is ongoing demand for novel agents. Approaches targeting cyclin-dependent kinases (CDK) have reached the clinical trial stage. CDK9 mediating RNA transcriptional elongation is the evolving pivotal CLL CDK inhibitor target. However, more CDK9 selective compounds are desirable. Here, we describe the CDK9 inhibitor LDC526 displaying a low nanomolar biochemical activity against CDK9 and an at least 50-fold selectivity against other CDKs. After demonstrating in vitro MEC-1 cell line and primary human CLL cell cytotoxicity we evaluated the LDC526 in vivo effect on human CLL cells transplanted into NOD/scid/γcnull (NSG) mice. LDC526 administration (75 mg/kg) for 5 days resulted in a 77% reduction of human CLL cells in NSG spleens compared to carrier control treatment. Next, we longitudinally studied the LDC526 impact on circulating CLL cells in the TCL1 transgenic mouse model. LDC526 (50 mg/kg) administration for two days led to a 16-fold reduction of blood CLL cell numbers. Remarkably, residual CLL cells exhibited significantly increased intracellular BCL-2 levels. However, the LDC526 cytotoxic effect was not restricted to CLL cells as also declining numbers of normal B and T lymphocytes were observed in LDC526 treated TCL1 mice. Taken together, our in vivo data provide a strong rational for continued LDC526 development in CLL therapy and argue for the combination with BCL-2 inhibitors.
Collapse
Affiliation(s)
- Joachim R Göthert
- Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
| | - Roze Imsak
- Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
| | - Michael Möllmann
- Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
| | - Stefanie Kesper
- Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
| | - Maria Göbel
- Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
| | - Ulrich Dührsen
- Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
| | - Arne Scholz
- Bayer AG, Pharmaceuticals, Drug Discovery, Berlin, Germany
| | - Ulrich Lücking
- Bayer AG, Pharmaceuticals, Drug Discovery, Berlin, Germany
| | | | - Anke Unger
- Lead Discovery Center GmbH (LDC), Dortmund, Germany
| | | | - Bert Klebl
- Lead Discovery Center GmbH (LDC), Dortmund, Germany
| | - Jan Eickhoff
- Lead Discovery Center GmbH (LDC), Dortmund, Germany
| | - Axel Choidas
- Lead Discovery Center GmbH (LDC), Dortmund, Germany
| | - Jan Dürig
- Department of Hematology, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
| |
Collapse
|
15
|
Izzo F, Schäfer M, Stockman R, Lücking U. A New, Practical One-Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides. Chemistry 2017; 23:15189-15193. [PMID: 28833686 PMCID: PMC5698725 DOI: 10.1002/chem.201703272] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Indexed: 01/14/2023]
Abstract
Unprotected tertiary sulfonimidamides have been prepared in good to excellent yields in a one-pot transformation from tertiary sulfinamides through NH transfer. The reaction is mediated by commercially available (diacetoxyiodo)benzene and ammonium carbamate in methanol under convenient conditions. A wide range of functional groups are tolerated and initial results indicate that the NH transfer is stereospecific. A small molecule X-ray analysis of NH sulfonimidamide 2 a and its behavior in selected in vitro assays in comparison to the matched sulfonamide are also reported. This new reaction provides a safe, short and efficient approach to sulfonimidamides, which have been the subject of recent, growing interest in the life sciences.
Collapse
Affiliation(s)
- Flavia Izzo
- School of ChemistryUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUnited Kingdom
| | - Martina Schäfer
- Bayer AGPharmaceuticals Division, Drug DiscoveryMüllerstr. 17813353BerlinGermany
| | - Robert Stockman
- School of ChemistryUniversity of NottinghamUniversity ParkNottinghamNG7 2RDUnited Kingdom
| | - Ulrich Lücking
- Bayer AGPharmaceuticals Division, Drug DiscoveryMüllerstr. 17813353BerlinGermany
| |
Collapse
|
16
|
Lücking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, Briem H, Terebesi I, Meyer K, Prelle K, Denner K, Bömer U, Schäfer M, Eis K, Valencia R, Ince S, von Nussbaum F, Mumberg D, Ziegelbauer K, Klebl B, Choidas A, Nussbaumer P, Baumann M, Schultz-Fademrecht C, Rühter G, Eickhoff J, Brands M. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem 2017; 12:1776-1793. [PMID: 28961375 PMCID: PMC5698704 DOI: 10.1002/cmdc.201700447] [Citation(s) in RCA: 95] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 09/26/2017] [Indexed: 12/25/2022]
Abstract
Selective inhibition of exclusively transcription‐regulating PTEFb/CDK9 is a promising new approach in cancer therapy. Starting from lead compound BAY‐958, lead optimization efforts strictly focusing on kinase selectivity, physicochemical and DMPK properties finally led to the identification of the orally available clinical candidate atuveciclib (BAY 1143572). Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats. BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clinical trials for the treatment of cancer.
Collapse
Affiliation(s)
- Ulrich Lücking
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Arne Scholz
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Philip Lienau
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Gerhard Siemeister
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Dirk Kosemund
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Rolf Bohlmann
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Hans Briem
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Ildiko Terebesi
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Kirstin Meyer
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Katja Prelle
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Karsten Denner
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Ulf Bömer
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Martina Schäfer
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Knut Eis
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Ray Valencia
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Stuart Ince
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Franz von Nussbaum
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Dominik Mumberg
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Karl Ziegelbauer
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| | - Bert Klebl
- Lead Discovery Center GmbH (LDC), Otto-Hahn-Str. 15, 44227, Dortmund, Germany
| | - Axel Choidas
- Lead Discovery Center GmbH (LDC), Otto-Hahn-Str. 15, 44227, Dortmund, Germany
| | - Peter Nussbaumer
- Lead Discovery Center GmbH (LDC), Otto-Hahn-Str. 15, 44227, Dortmund, Germany
| | - Matthias Baumann
- Lead Discovery Center GmbH (LDC), Otto-Hahn-Str. 15, 44227, Dortmund, Germany
| | | | - Gerd Rühter
- Lead Discovery Center GmbH (LDC), Otto-Hahn-Str. 15, 44227, Dortmund, Germany
| | - Jan Eickhoff
- Lead Discovery Center GmbH (LDC), Otto-Hahn-Str. 15, 44227, Dortmund, Germany
| | - Michael Brands
- Bayer AG, Pharmaceuticals Division, Drug Discovery, Müllerstr. 178, 13353, Berlin, Germany
| |
Collapse
|
17
|
Sirvent JA, Lücking U. Cover Picture: Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates (ChemMedChem 7/2017). ChemMedChem 2017. [DOI: 10.1002/cmdc.201700179] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - Ulrich Lücking
- Drug Discovery; Bayer AG; Müllerstr. 178 13353 Berlin Germany
| |
Collapse
|
18
|
Sirvent JA, Lücking U. Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates. ChemMedChem 2017; 12:487-501. [PMID: 28221724 PMCID: PMC5485063 DOI: 10.1002/cmdc.201700044] [Citation(s) in RCA: 135] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Indexed: 01/17/2023]
Abstract
Sulfoximines have gained considerable recognition as an important structural motif in drug discovery of late. In particular, the clinical kinase inhibitors for the treatment of cancer, roniciclib (pan-CDK inhibitor), BAY 1143572 (P-TEFb inhibitor), and AZD 6738 (ATR inhibitor), have recently drawn considerable attention. Whilst the interest in this underrepresented functional group in drug discovery is clearly on the rise, there remains an incomplete understanding of the medicinal-chemistry-relevant properties of sulfoximines. Herein we report the synthesis and in vitro characterization of a variety of sulfoximine analogues of marketed drugs and advanced clinical candidates to gain a better understanding of this neglected functional group and its potential in drug discovery.
Collapse
|
19
|
Lücking U, Sirvent J, Bierer D, Webster R. Palladium-Catalyzed Direct α-Arylation of p-Methoxybenzyl-Protected S,S-Dimethylsulfoximine. SYNTHESIS-STUTTGART 2016. [DOI: 10.1055/s-0036-1588894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Ayaz P, Andres D, Kwiatkowski DA, Kolbe CC, Lienau P, Siemeister G, Lücking U, Stegmann CM. Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9. ACS Chem Biol 2016; 11:1710-9. [PMID: 27090615 DOI: 10.1021/acschembio.6b00074] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Roniciclib (BAY 1000394) is a type I pan-CDK (cyclin-dependent kinase) inhibitor which has revealed potent efficacy in xenograft cancer models. Here, we show that roniciclib displays prolonged residence times on CDK2 and CDK9, whereas residence times on other CDKs are transient, thus giving rise to a kinetic selectivity of roniciclib. Surprisingly, variation of the substituent at the 5-position of the pyrimidine scaffold results in changes of up to 3 orders of magnitude of the drug-target residence time. CDK2 X-ray cocrystal structures have revealed a DFG-loop adaption for the 5-(trifluoromethyl) substituent, while for hydrogen and bromo substituents the DFG loop remains in its characteristic type I inhibitor position. In tumor cells, the prolonged residence times of roniciclib on CDK2 and CDK9 are reflected in a sustained inhibitory effect on retinoblastoma protein (RB) phosphorylation, indicating that the target residence time on CDK2 may contribute to sustained target engagement and antitumor efficacy.
Collapse
Affiliation(s)
- Pelin Ayaz
- Bayer Pharma AG, Drug Discovery, Lead Discovery
Berlin, Berlin, Germany
| | - Dorothee Andres
- Bayer Pharma AG, Drug Discovery, Lead Discovery
Berlin, Berlin, Germany
| | | | | | - Philip Lienau
- Bayer Pharma AG, Drug Discovery, Research Pharmacokinetics, Berlin, Germany
| | | | - Ulrich Lücking
- Bayer Pharma AG, Drug Discovery, Medicinal Chemistry, Berlin, Germany
| | | |
Collapse
|
21
|
Sugawara T, Lejeune P, Köhr S, Neuhaus R, Faus H, Gelato KA, Busemann M, Cleve A, Lücking U, von Nussbaum F, Brands M, Mumberg D, Jung K, Stephan C, Haendler B. BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients. Oncotarget 2016; 7:6015-28. [PMID: 26760770 PMCID: PMC4868737 DOI: 10.18632/oncotarget.6864] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Accepted: 12/24/2015] [Indexed: 11/25/2022] Open
Abstract
Androgen receptor (AR) mutations arise in patients developing resistance to hormone deprivation therapies. Here we describe BAY 1024767, a thiohydantoin derivative with strong antagonistic activity against nine AR variants with mutations located in the AR ligand-binding domain (LBD), and against wild-type AR. Antagonism was maintained, though reduced, at increased androgen levels. Anti-tumor efficacy was evidenced in vivo in the KuCaP-1 prostate cancer model which bears the W741C bicalutamide resistance mutation and in the syngeneic prostate cancer rat model Dunning R3327-G. The prevalence of six selected AR mutations was determined in plasma DNA originating from 100 resistant patients and found to be at least 12%. Altogether the results show BAY 1024767 to be a strong antagonist for several AR mutants linked to therapy resistance, which opens the door for next-generation compounds that can benefit patients based on their mutation profile.
Collapse
Affiliation(s)
| | | | - Silke Köhr
- Global Drug Discovery, Bayer Pharma AG, Berlin, Germany
| | | | | | | | | | - Arwed Cleve
- Global Drug Discovery, Bayer Pharma AG, Berlin, Germany
| | | | | | | | | | - Klaus Jung
- Berlin Institute of Urologic Research, Berlin, Germany
- Department of Urology, Charité University Hospital, Berlin, Germany
| | - Carsten Stephan
- Berlin Institute of Urologic Research, Berlin, Germany
- Department of Urology, Charité University Hospital, Berlin, Germany
| | | |
Collapse
|
22
|
Scholz A, Lücking U, Siemeister G, Lienau P, Eis K, Wengner A, Petersen K, Bömer U, Nussbaumer P, Choidas A, Rühter G, Eickhoff J, Schultz-Fademrecht C, Klebl B, Ince S, Nussbaum FV, Mumberg D, Brands M, Ziegelbauer K. Abstract 4538: BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-4538] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The family of cyclin-dependent kinase (CDK) proteins consists of multiple cell cycle regulating CDK members as well as members involved in the regulation of gene transcription like CDK9/PTEFb (positive transcription elongation factor b). Inhibition of PTEFb and its direct downstream target RNA polymerase II is thought to cause rapid depletion of short-lived mRNA transcripts of important survival proteins like c-myc and Mcl-1 and thereby to induce growth delay and apoptosis in addicted tumor cells.
In contrast to pan-CDK inhibitiors which are currently evaluated in Phase I and II clinical trials, PTEFb selective inhibitors have not been explored for clinical utility.
BAY 1112054 is a potent and highly selective PTEFb-kinase inhibitor with low nanomolar activity against PTEFb/CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. Furthermore, BAY 1112054 shows a favourable selectivity against non-CDK kinases in vitro. The compound exhibits broad anti-proliferative activity against a panel of tumor cell lines with sub-micromolar IC-50 values.
In line with the proposed mode of action, a concentration-dependent inhibition of the phosphorylation of the RNA polymerase II was observed in A549 tumor cells. This inhibition was accompanied by a reduction of intracellular Mcl-1 protein levels. Furthermore, BAY 1112054 increased DNA fragmentation in synchronized HeLa cells upon compound treatment for 24 hours.
BAY 1112054 showed convincing in vivo efficacy at tolerated doses in two xenograft models in mice. Once daily oral treatment led to complete tumor stasis in established MOLM-13 AML xenografts. Pharmacokinetic analysis revealed that unbound plasma levels were 8 to 12 hours above the cellular IC50 in this model. In vivo efficacy and tolerability of the once daily po schedule of BAY 1112054 was confirmed in NCI-H82 SCLC xenografts. Xenografted tumors of this model showed lower levels of RNA polymerase II phosphorylation and Mcl-1 upon treatment with BAY 1112054.
In conclusion, our data provides in vitro and in vivo proof of concept for BAY 1112054, a potent and highly selective inhibitor of PTEFb/CDK9 with first-in-class potential, and warrant further clinical evaluation of PTEFb selective inhibitors for the treatment of cancers addicted to the transcription of short-lived anti-apoptotic survival proteins.
Citation Format: Arne Scholz, Ulrich Lücking, Gerhard Siemeister, Philip Lienau, Knut Eis, Antje Wengner, Kirstin Petersen, Ulf Bömer, Peter Nussbaumer, Axel Choidas, Gerd Rühter, Jan Eickhoff, Carsten Schultz-Fademrecht, Bert Klebl, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Michael Brands, Karl Ziegelbauer. BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4538. doi:10.1158/1538-7445.AM2014-4538
Collapse
Affiliation(s)
| | | | | | | | - Knut Eis
- 1Bayer Pharma AG, Berlin, Germany
| | | | | | | | | | | | - Gerd Rühter
- 2Lead Discovery Center GmbH, Dortmund, Germany
| | | | | | - Bert Klebl
- 2Lead Discovery Center GmbH, Dortmund, Germany
| | | | | | | | | | | |
Collapse
|
23
|
|
24
|
|
25
|
Lücking U, Jautelat R, Krüger M, Brumby T, Lienau P, Schäfer M, Briem H, Schulze J, Hillisch A, Reichel A, Wengner AM, Siemeister G. Cover Picture: The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer (ChemMedChem 7/2. ChemMedChem 2013. [DOI: 10.1002/cmdc.201390025] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
26
|
Lücking U, Jautelat R, Krüger M, Brumby T, Lienau P, Schäfer M, Briem H, Schulze J, Hillisch A, Reichel A, Wengner AM, Siemeister G. The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer. ChemMedChem 2013; 8:1067-85. [PMID: 23671017 DOI: 10.1002/cmdc.201300096] [Citation(s) in RCA: 127] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2013] [Revised: 04/19/2013] [Indexed: 11/08/2022]
Abstract
Lead optimization of a high-throughput screening hit led to the rapid identification of aminopyrimidine ZK 304709, a multitargeted CDK and VEGF-R inhibitor that displayed a promising preclinical profile. Nevertheless, ZK 304709 failed in phase I studies due to dose-limited absorption and high inter-patient variability, which was attributed to limited aqueous solubility and off-target activity against carbonic anhydrases. Further lead optimization efforts to address the off-target activity profile finally resulted in the introduction of a sulfoximine group, which is still a rather unusual approach in medicinal chemistry. However, the sulfoximine series of compounds quickly revealed very interesting properties, culminating in the identification of the nanomolar pan-CDK inhibitor BAY 1000394, which is currently being investigated in phase I clinical trials.
Collapse
Affiliation(s)
- Ulrich Lücking
- Bayer Pharma AG, Global Drug Discovery, Medicinal Chemistry, 13353 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Siemeister G, Lücking U, Wengner AM, Lienau P, Steinke W, Schatz C, Mumberg D, Ziegelbauer K. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol Cancer Ther 2012; 11:2265-73. [PMID: 22821149 DOI: 10.1158/1535-7163.mct-12-0286] [Citation(s) in RCA: 106] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Deregulated activity of cyclin-dependent kinases (CDK) results in loss of cell-cycle checkpoint function and increased expression of antiapoptotic proteins, which has been directly linked to the molecular pathology of cancer. BAY 1000394 inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC(50) values in the range between 5 and 25 nmol/L. Cell proliferation was inhibited at low nanomolar concentration in a broad spectrum of human cancer cell lines. In cell-based assays, the inhibition of phosphorylation of the CDK substrates retinoblastoma protein, nucleophosmin, and RNA polymerase II was shown. Cell-cycle profiles were consistent with inhibition of CDK 1, 2, and 4 as shown in cell-cycle block and release experiments. The physicochemical and pharmacokinetic properties of BAY 1000394 facilitate rapid absorption and moderate oral bioavailability. The compound potently inhibits growth of various human tumor xenografts on athymic mice including models of chemotherapy resistance upon oral dosing. Furthermore, BAY 1000394 shows more than additive efficacy when combined with cisplatin and etoposide. These results suggest that BAY 1000394 is a potent pan-CDK inhibitor and a novel oral cytotoxic agent currently in phase I clinical trials.
Collapse
Affiliation(s)
- Gerhard Siemeister
- Bayer Pharma AG, Global Drug Discovery/TRG-ONC/GT, Mullerstrasse 178, D-13342 Berlin, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Siemeister G, Wengner A, Lücking U, Lienau P, Steinke W, Schatz C, Mumberg D, Ziegelbauer K. 495 Pharmacological profile of the novel pan-CDK inhibitor BAY 1000394 in tumor models of human small cell lung cancer, breast and prostate cancer as monotherapy and combination treatment. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72202-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
29
|
Missner E, Bahr I, Badock V, Lücking U, Siemeister G, Donner P. Off-target decoding of a multitarget kinase inhibitor by chemical proteomics. Chembiochem 2009; 10:1163-74. [PMID: 19350611 DOI: 10.1002/cbic.200800796] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Unbiased: Chemical proteomics was used to profile compound interactions in an unbiased fashion. We present here the application of different compound-immobilization routes for decoding nonprotein kinase off-targets of the multitarget kinase inhibitor C1, which interacts with distinct compound moieties. Since the approval of the first selective tyrosine kinase inhibitor, imatinib, various drugs have been developed to target protein kinases. However, due to a high degree of structural conservation of the ATP binding site, off-target effects have been reported for several drugs. Here, we report on off-target decoding for a multitarget protein kinase inhibitor by chemical proteomics, by focusing on interactions with nonprotein kinases. We tested two different routes for the immobilization of the inhibitor on a carrier matrix, and thus identified off-targets that interact with distinct compound moieties. Besides several of the kinases known to bind to the compound, the pyridoxal kinase (PDXK), which has been described to interact with the CDK inhibitor (R)-roscovitine, was captured. The PDXK-inhibitor interaction was shown to occur at the substrate binding site rather than at the ATP binding site. In addition, carbonic anhydrase 2 (CA2) binding was demonstrated, and the determination of the IC(50) revealed an enzyme inhibition in the submicromolar range. The data demonstrate that different compound immobilization routes for chemical proteomics approaches are a valuable method to improve the knowledge about the off-target profile of a compound.
Collapse
Affiliation(s)
- Enrico Missner
- Bayer Schering Pharma AG, Global Drug Discovery, 13342 Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
30
|
Lücking U, Siemeister G, Schäfer M, Briem H, Krüger M, Lienau P, Jautelat R. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities. ChemMedChem 2008; 2:63-77. [PMID: 17131463 DOI: 10.1002/cmdc.200600199] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
X-ray structures from CDK2-aminopyrimidine inhibitor complexes led to the idea to stabilize the active conformation of aminopyrimidine inhibitors by incorporating the recognition site into a macrocyclic framework. A modular synthesis approach that relies on a new late-stage macrocyclization protocol that enables fast and efficient synthesis of macrocyclic aminopyrimidines was developed. A set of structurally diverse derivatives was prepared. Macrocyclic aminopyrimidines were shown to be multitarget inhibitors of CDK1/2 and VEGF-RTKs. In addition, potent antiproliferative activities toward various human tumor cells and a human tumor xenograft model were demonstrated.
Collapse
Affiliation(s)
- Ulrich Lücking
- Medicinal Chemistry, Research Center Europe, Schering AG, 13342 Berlin, Germany.
| | | | | | | | | | | | | |
Collapse
|
31
|
|
32
|
Jautelat R, Brumby T, Schäfer M, Briem H, Eisenbrand G, Schwahn S, Krüger M, Lücking U, Prien O, Siemeister G. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. Chembiochem 2005; 6:531-40. [PMID: 15742375 DOI: 10.1002/cbic.200400108] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Rolf Jautelat
- Medicinal Chemistry, Research Center Europe, Schering AG, 13342 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Siemeister G, Briem H, Brumby T, Haberey M, Jautelat R, Krüger M, Lücking U, Reichel A, Schäfer M, Bosslet K. 416 Simultaneous targeting of tumor cell proliferation and tumor-induced neoangiogenesis by the novel CDK2/VEGF-RTK dual pathway inhibitor ZK-CDK. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80424-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
34
|
Abstract
The synthesis and characterization of novel metallocavitand 6 are described. This is a covalent hybrid of a deepened, self-folding cavity and a Zn-phenanthroline fragment. Host 6 features a large molecular cavity of approximately 8 x 10 A dimensions, and the metal binding site is directed in toward the cavity. Binding abilities of the metallocavitand in solution was demonstrated for quinuclidine 11 and Dabco 12 using UV-vis and 1H NMR spectroscopy. Intramolecular hydrogen bonds at the upper rims of cavitand 6 resist the unfolding of the inner cavities and thereby increase the energetic barrier to guest exchange. The exchange is slow on the NMR time scale (at ambient temperatures, CD2Cl2), and kinetically stable complexes result. Both the polyaromatic cavity and metallosite participate simultaneously in the binding event. Zinc-containing deep cavities may be attractive as catalytic chambers for hydrolysis and esterification.
Collapse
Affiliation(s)
- U Lücking
- The Skaggs Institute for Chemical Biology, MB-26, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
| | | | | | | |
Collapse
|
35
|
|
36
|
Affiliation(s)
- Ulrich Lücking
- Contribution from The Skaggs Institute for Chemical Biology and The Department of Chemistry, The Scripps Research Institute, MB-26, 10550 North Torrey Pines Road, La Jolla, California 92037
| | - Fabio C. Tucci
- Contribution from The Skaggs Institute for Chemical Biology and The Department of Chemistry, The Scripps Research Institute, MB-26, 10550 North Torrey Pines Road, La Jolla, California 92037
| | - Dmitry M. Rudkevich
- Contribution from The Skaggs Institute for Chemical Biology and The Department of Chemistry, The Scripps Research Institute, MB-26, 10550 North Torrey Pines Road, La Jolla, California 92037
| | - Julius Rebek
- Contribution from The Skaggs Institute for Chemical Biology and The Department of Chemistry, The Scripps Research Institute, MB-26, 10550 North Torrey Pines Road, La Jolla, California 92037
| |
Collapse
|
37
|
Baeschlin DK, Chaperon AR, Charbonneau V, Green LG, Ley SV, Lücking U, Walther E. Effiziente Synthese von Oligosacchariden: Totalsynthese eines Glycosylphosphatidyl‐ inosit‐Ankers aus
Trypanosoma brucei. Angew Chem Int Ed Engl 1999. [DOI: 10.1002/(sici)1521-3757(19981217)110:24<3609::aid-ange3609>3.0.co;2-#] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Daniel K. Baeschlin
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (Großbritannien), Fax: (+44) 1223‐336442
| | - André R. Chaperon
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (Großbritannien), Fax: (+44) 1223‐336442
| | - Virginie Charbonneau
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (Großbritannien), Fax: (+44) 1223‐336442
| | - Luke G. Green
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (Großbritannien), Fax: (+44) 1223‐336442
| | - Steven V. Ley
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (Großbritannien), Fax: (+44) 1223‐336442
| | - Ulrich Lücking
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (Großbritannien), Fax: (+44) 1223‐336442
| | - Eric Walther
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (Großbritannien), Fax: (+44) 1223‐336442
| |
Collapse
|
38
|
Baeschlin DK, Chaperon AR, Charbonneau V, Green LG, Ley SV, Lücking U, Walther E. Rapid Assembly of Oligosaccharides: Total Synthesis of a Glycosylphosphatidylinositol Anchor ofTrypanosoma brucei. Angew Chem Int Ed Engl 1998; 37:3423-3428. [DOI: 10.1002/(sici)1521-3773(19981231)37:24<3423::aid-anie3423>3.0.co;2-i] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/1998] [Indexed: 11/07/2022]
|
39
|
Baeschlin DK, Chaperon AR, Charbonneau V, Green LG, Ley SV, Lücking U, Walther E. Rapid Assembly of Oligosaccharides: Total Synthesis of a Glycosylphosphatidylinositol Anchor of Trypanosoma brucei. Angew Chem Int Ed Engl 1998. [PMID: 29711276 DOI: 10.1002/(sici)1521-3773(19981231)37:24<3423::aid-anie3423>3.3.co;2-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Six building blocks, six reaction steps: The recently developed innovative methodology facilitated the convergent synthesis of the complex oligosaccharide core 1 (shown here with protecting groups) for the total synthesis of a glycosylphosphatidylinositol (GPI) anchor. The key factors are the tuning of the reactivity of the building blocks by using 1,2-diacetal protecting groups and the desymmetrization of glycerol and myo-inositol with a chiral bis(dihydropyran).
Collapse
Affiliation(s)
- Daniel K Baeschlin
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (UK), Fax: (+44) 1223-336442
| | - André R Chaperon
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (UK), Fax: (+44) 1223-336442
| | - Virginie Charbonneau
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (UK), Fax: (+44) 1223-336442
| | - Luke G Green
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (UK), Fax: (+44) 1223-336442
| | - Steven V Ley
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (UK), Fax: (+44) 1223-336442
| | - Ulrich Lücking
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (UK), Fax: (+44) 1223-336442
| | - Eric Walther
- Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW (UK), Fax: (+44) 1223-336442
| |
Collapse
|
40
|
Douglas NL, Ley SV, Lücking U, Warriner SL. Tuning glycoside reactivity: New tool for efficient oligosaccharide synthesis. ACTA ACUST UNITED AC 1998. [DOI: 10.1039/a705275h] [Citation(s) in RCA: 234] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|